drugset / Trial / NCT07049458

Study of CHO-A04 in Advanced Solid Tumors

NCT07049458 ↗

Phase 1/2 Not yet recruiting 62 enrolled Cho Pharma Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment. The main questions it aims to answer are: * Which dose of CHO-A04 shows the best anti-cancer ability? * How will your body respond to CHO-A04 treatment? * How long will CHO-A04 remain in your body? There are two stages of investigation in this study: * Phase I: to find the best anti-cancer dose of CHO-A04 * Phase IIa: to find the CHO-A04 anti-cancer ability in specific cancer types In this study, each participant will be assigned to one of the CHO-A04 dose levels. Participants will have CHO-A04 infusion via blood vessel once every week for four weeks. The CHO-A04 treatment may continue based on participants' condition and CHO-A04 safety evaluations.

Timeline

Start
2025-12-01
Primary completion
2027-10-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CHO-A04 Unknown 0.5 mg/kg Intravenous
Subject CHO-A04 Unknown 1 mg/kg Intravenous
Subject CHO-A04 Unknown 2 mg/kg Intravenous
Subject CHO-A04 Unknown 4 mg/kg Intravenous
Subject CHO-A04 Unknown 8 mg/kg Intravenous
Subject CHO-A04 Unknown 12 mg/kg Intravenous

Indications